Avanir gets $40 to wrap new Phase III for Zenvia

A group of venture firms led by ProQuest Investors is providing Avanir Pharmaceuticals with $40 million to fund a confirmatory late-stage trial of Zenvia and a full response to the FDA's request for more data. Avanir will issue an aggregate of approximately 35 million shares at a price of $1.14 per share unit--the market closing bid price as of March 26, 2008 plus a nominal amount for warrants--with 35 percent warrant coverage. The warrants, which represent the right to acquire up to approximately 12.2 million shares, are exercisable at 125 percent of the offering price and have a 5-year exercise term.

Avanir has had a hard time developing Zenvia, an experimental drug for involuntary emotional expression disorder. The FDA handed the biotech an approvable letter for the drug in late 2006 which outlined a demand for new data on the drug.

- read the press release

ALSO: Germany's Pieris has raised $38 million in its second round of venture financing led by OrbiMed Advisers. Pieris is developing a novel class of targeted human protein therapeutics. Release

PLUS: Durham, NC-based Scynexis has raised $13.5 million from a group of investors that include a lineup of Big Pharma companies. Report

Related Articles:
Avanir shares soar on positive Zenvia data. Report
CEO heads for exit after Avanir stocks plunge. Report
Avanir pockets $10M with AstraZeneca deal. Report
Avanir slashes jobs, puts Zenvia on ice. Report
Avanir slashes costs as it mulls asset sale. Report

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."